Rice University scientists have achieved the total synthesis of a scarce natural marine product that may become a powerful cancer-fighting agent – the molecule shishijimicin A.
A group led by world-renowned Rice chemist K.C. Nicolaou announced the successful synthesis this month in the Journal of the American Chemical Society.
The complex organic molecule was discovered in a rare sea squirt, Didemnum proliferum, more than a decade ago. Lab tests at the time proved it to be more than 1,000 times as toxic to cancer cells as the anticancer drug taxol (aka paclitaxel), but its scarcity did not provide amounts sufficient for extensive biological studies and clinical trials.
For that, chemists needed to design and develop the many steps required to synthesize the molecule, a specialty for which Nicolaou is well-known. Nicolaou, who joined Rice in 2013, is noted for achieving the first synthesis of taxol as well as the synthesis of the highly cytotoxic compound calicheamicin, which was used in the first antibody-drug conjugate (ADC) for targeted chemotherapy.
Nicolaou said shishijimicin shows just as much potential – and perhaps more – for cancer treatment via “Trojan horse”-style ADCs tuned to target specific types of cancer. “Because it’s so potent, you may only need one or two molecules to get into a cancer cell to do the job,” he said.
Such toxins kill cancer cells by cleaving their DNA or freezing their cytoskeletons to prevent them from replicating, he said.
The path to synthesis took a rapid two years because much of the groundwork had already been set by Nicolaou’s basic work three decades ago in the total synthesis of calicheamicin.
“All the fundamental science for the shishijimicin project was done in the 1990s,” he said. “What we synthesized then was too toxic to be used, but now it has revitalized the whole field because biologists and clinicians can selectively target cancer cells (with ADCs). If we hadn’t done the fundamental science so many years ago, it would have taken us so much longer to come to the same point.”
Nicolaou said his prime concern, in addition to facilitating biology and medicine, is to advance the field of synthetic chemistry. “If we don’t advance it now, we won’t be able to make the complex molecules of the future,” he said. “We have to continue to sharpen the tools of organic synthesis.”
Nicolaou said the next steps for shishijimicin are to streamline its synthesis and add chemical handles so it can be attached to antibodies for delivery to cancer cells. “We’ve established the beachhead with the first total synthesis,” he said. “Now we aim to optimize the process to make it more practical and apply it to synthesize variations of the molecule.”
Then it will be up to partner pharmaceutical companies to develop the compound for eventual clinical trials. They won’t need much, Nicolaou said. “If they have a few hundred milligrams – a fraction of a gram – they can take it to clinical trials, because it’s so potent,” he said. “And now they have hundreds of antibodies selected for different kinds of cancer. My hope is that our molecule will lead to an effective drug for personalized medicine.”
Rice postdoctoral researchers Zhaoyong Lu, James Woods and Te-ik Sohn and graduate student Ruofan Li are co-authors of the paper. Nicolaou is Rice’s Harry C. and Olga K. Wiess Professor of Chemistry.
The Cancer Prevention and Research Institute of Texas and the Welch Foundation supported the research.
Baylor College of MedicineBaylorCollegeOfMedicine
Congratulations to Dr. Xiang Zhang on being the 2018 Sue Eccles Young Investigator Award recipient from the Metastasis Research Society. #research #awards
Start off your morning on a tropical note with our Sugar, Heart, and Life Program's mango shake! https://t.co/TQxtiWD5yO
New memorial for paratroopers dedicated at Miramar @VANatCemeteries https://t.co/E15jycKj5X via @sdut
Are you on LinkedIn? Be sure to follow Rice University! https://t.co/aZqRiSLgYI
MD Anderson Cancer Center@MDAndersonNews
“#Lynchsyndrome is seriously underdiagnosed.” Learn how one of our doctors is helping raise awareness for a genetic syndrome that increases #cancer risk: https://t.co/yTyF65p0Zr #endcancer https://t.co/70Ok973o84
From baldness & infertility to high blood pressure & increased risk of heart attack, the side effects of steroid use may have a more serious health impacts than you thought.
Legacy project to tell the stories of Veterans interred at Riverside @VANatCemeteries https://t.co/Tu7MCotplc via #VAntagePoint
RT @culturemap: Medical Center's magical Match Day means start of Houstonians' dreams https://t.co/thisTyCaGe
RT @UTCVSurgery: Dr. Tom Nguyen Awarded First Place for #ACC’s Transcatheter Heart Valve Handbook! Read more here: https://t.co/P9Vz8iq6wi
RT @UTCVSurgery: Have you registered for The Inaugural Houston AFib Patient Experience Seminar yet? Read more here: https://t.co/Z0a8ftrol…
The Hurricane Harvey Relief Fund has awarded $2.6 million to The University of Texas Health Science Center at Houston (UTHealth) for a technology-supported program for patients with unmet post-Harvey behavioral health needs.
University of Houston@UHouston
@ohnosydneylo It’s perfect! https://t.co/A7jp3WeclR
U.S. Department of Veterans AffairsVeteransAffairs
Today's #VeteranOfTheDay is Army Veteran Les Payne. Les was born July 12, 1941 in Tuscaloosa, Alabama. He received a degree from University of Connecticut in 1964 and went on to serve in the Vietnam War during a tour with the Army. After his time in the military, Les joined Newsday in 1969. Les was part of the Newsday reporting team that created a 33-part series tracking heroin from growth in Turkey to being sold in America. "The Heroin Trail" won a Pulitzer Prize in 1974. Les was a founding member and former president of the National Association of Black Journalists. He retired in 2006, spending nearly four decades at Newsday and setting the standard for excellent journalism. Les died Monday night at his home in Harlem. We honor his service.
Today's #VeteranOfTheDay is @USArmy Veteran Les Payne. Les was a founder and former president of @NABJ, @PulitzerPrizes winner, and long time reporter for @Newsday.
Billing issues. Call center unable to help & there is simply no complaints or escalation number!!!!